Siemens Healthcare Diagnostics Gmbh

Bayer Corporation

Miles Inc.

Bayer Healthcare LLC

Bayer Corporaton

Michael J Pugia

James Arthur Profitt

Chris Thomas Zimmerle

Lloyd S Schulman

Gert Blankenstein

James P Albarella

Ralf-Peter Peters

Paul F Corey

Ronald G Sommer

Gary E Rehm

Karen L Marfurt

Rui Ma

Robert J Schaeper

Todd K Cast

Julia Philip

Steven W Felman

Holger Bartos

Marvin A Genshaw

Hai-Hang Kuo

Michael Salvati

Linda Anderson-Mauser

Sally E Cahill

Koleen K Messenger

Solomon H Murphy

Shannon Gleason

Sung-Kwon Jung

Karlheinz Hildenbrand

Robert P Hatch

Pratap Singh

J Oakey Noell

Gary M Johnson

Spencer Lin

Angela A Michaels

Karl-Heinz Hildenbrand

Spencer H Lin

Christos Galiatsatos

James Noffsinger

Melvin D Smith

Rena A Ide

Karen Marfut

Hai Hang Kuo

Henry Lu

Jane F Wallace

Manju Basu

The timing of the reaction of moisture-sensitive reagents for detecting the presence of analytes, e.g. leukocytes in urine samples, is used to detect when the reagents have been compromised by excess humidity. The ratio of light reflectance at wavelengths characteristic of the products of reaction between the reagents and the analyte and an infra-red reference dye is measured at two preset times after a urine sample has been applied to a test strip and used to determine whether the reagents have been compromised by excessive humidity. The presence of unusually dark samples is determined from the reflected light at 470 and 625 nm in order to confirm that the test strips are humidity-compromised.

Device and method for detection of humidity-compromised urine test strips

Particles are released from a particle-containing area of a first surface of a porous matrix. The particle-containing area is contacted with a liquid medium and sonic energy is applied to an opposing area on a second surface of the porous matrix, wherein the opposing area is opposite to the particle-containing area. The particles may be biological particles or non-biological particles.

Particle release and collection

A cell response assay for cancer is provided. In the assay, the levels of a cancer cell type biomarker, a chemo resistance biomarker and a metastatic potential biomarker are simultaneously measured in a biological sample.

Cell response assay for cancer and methods of producing and using same

A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.

Rare molecule detection

There is provided a system () and method () for improving ICC and/or ISH rare cell detection by lowering background noise and providing enhanced detection of rare cells (). In an embodiment, background noise for an ICC and/or an ISH rare cell detection assay is reduced and rare cell signaling is enhanced via feedback control. To accomplish the feedback control, an electronic control circuit () can direct a fluid delivery apparatus () to add an adjustment amount to account for fluid loss in the system () when fluid loss is indicated.

Feedback control for improved rare cell detection

Nucleic acids in non-rare cells in a sample containing non-rare cells and rare cells are selectively released from the non-rare cells. The sample is combined with an aqueous medium, and the combination is held for a period of time and at a temperature for selectively releasing nucleic acids from the non-rare cells but not from the rare cells. The sample is subjected to filtration to separate rare cells from non-rare cells. Rare cells with intact nucleic acids are separated from non-rare cells and nucleic acids from the non-rare cells. Nucleic acids from the rare cells are subjected to one or more identification techniques either with or without extraction of nucleic acids from the rare cells.

Selective nucleic acid separation

A ratio of rare cells to non-rare cells in a blood sample suspected of containing rare cells and non-rare cells is enhanced. A treated blood sample is prepared by providing in combination the blood sample, a platelet deactivation agent, a fibrin-formation-arresting agent and fibrin in an amount sufficient to cause a predetermined level of agglutination of the rare cells. The treated blood sample is then contacted with a porous matrix such that agglutinated rare cells are preferentially retained on the porous matrix. The rare cells may then be identified.

Rare cell concentration

Sample media for the analysis of analytes in a fluid test sample includes a carrier, at least one test field on the surface of the carrier including at least one reagent reactive with the analytes and capable of providing a detectable response. A non-visible bar code formed by at least two distinct non-visible marker fields is located on the carrier. The marker fields are configured to reflect electro-magnetic (EM) radiation within one or more ranges of non-visible wavelengths to form a coded sequence of reflectances correlated to identification of the sample media.

Non-visible detectable marking for medical diagnostics

A substrate, which is useful for performing biological, chemical and diagnostic assays, and a method for preparing the substrate are provided. The substrate has an upper surface with a coating disposed thereon. The coating comprises a charged polymer, a non-ionic polyether, and a silicate compound. The substrate can increase capture phase binding and reduce non-specific binding of biomolecules for a biological microarray.

Coated substrates for high energy capture phase binding and methods of production and use thereof

Methods of detecting a first species' Ig-CTF in a biological sample comprising exposing the biological sample to a first antibody of a second species that preferentially binds the first species' Ig-CTF or an antigen binding fragment of the antibody, forming a mixture, exposing the mixture to a second antibody or antigen-binding fragment of a third species that preferentially binds the first species' Ig, and detecting the Ig-CTF in the biological sample.

Adiponectin receptor C-terminal fragments (CTF)-immunoglobulin

A coating formula and method for surface coating non-porous surfaces. Microfluidic devices including said coating achieve desired properties including increased hydrophilicity, improved adhesion, stability and optical clarity.

Hydrophilic coating for nonporous surfaces and microfluidic devices including same

Methods are disclosed for determining progression of a condition, onset of a condition, or efficacy of treatment of a condition characterized by an adipocyte imbalance in a patient. In addition, methods are disclosed of treating diabetes, abnormal adipocyte activity, and insulin resistance using monomeric, homodimeric, and heterodimeric forms of certain C-terminal fragments of adiponectin receptor. In addition, methods of treating abnormal adipocyte activity, treating metabolic syndrome, causing insulin secretion, increasing insulin levels, inhibiting insulin degradation enzyme, treating Alzheimer's disease, treating cardiovascular disease associated with adiponectin levels, inhibiting ADAM-17 enzyme, inhibiting a protease, treating a condition associated with TNF-alpha, and treating a condition associated with HER2-neu are disclosed. Compositions, dosage forms, and kits are also disclosed.

Monomeric and dimeric forms of adiponectin receptor fragments and methods of use

The present invention relates to soluble C-terminal fragments of the adiponectin receptor and their use in the diagnosis and management of disorders.

Detection of soluble adiponectin receptor peptides and use in diagnosis and therapeutics

Growing community of inventors

Granger, IN, United States of America

Michael J Pugia